Hair Repigmentation Associated With the Use of Brentuximab

The document reported a case where a 72-year-old man experienced partial hair repigmentation from white to dark gray after 10 months of treatment with brentuximab vedotin for chronic graft-versus-host disease. This change persisted for over a year. The mechanism was unclear, but it was suggested that brentuximab might influence melanogenesis by affecting proinflammatory cytokines. Further research was needed to understand the mechanisms and clinical scenarios of medication-induced hair repigmentation.